Brief: PCI Biotech H1 Operating Loss At NOK 38.4 Million
Aug 31 (Reuters) - PCI Biotech Holding ASA PCIB.OL :
* REG-PCI BIOTECH INTERIM FIRST-HALF YEAR 2022 RESULTS
* H1 OPERATING LOSS NOK 38.4 MILLION VERSUS LOSS NOK 40.3
MILLION
YEAR AGO
Source text for Eikon: ID:nGNE1H1LLc
Further company coverage: PCIB.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on PCI Biotech Holding ASA
See all newsBrief: Euronext Oslo Børs To Delist PCI Biotech Holding Shares
Brief: Euronext Oslo Børs Gets Application From PCI Biotech Holding For Delisting
Brief: PCI Biotech Holding Board Proposes Dissolution, Delisting
Brief: Oslo Bors: PCI Biotech Holding Is Placed In Recovery Box
Brief: PCI Biotech Says Co Initiates Process To Evaluate Opportunity For Structured Wind-Up Process